Company Overview and News
10:15 am Market Outlook: Rajesh Palviya, Head – Technical & Derivatives Analyst of Axis Securities said, "Given the sharp rise in October 2017, we expect the market to consolidate in the next two months. Important events lined up are state elections and their outcome which is expected to be major event infusing volatility in the market,"
Future Market Insights has conducted a comprehensive study of the global geosynthetics market in its recent report 'Geosynthetics Market: Global Industry Analysis 2012-2016 and Opportunity Assessment 2017-2027'. The geosynthetics market is expected to grow at an exponential CAGR of 10.1% for the forecast period and be worth more than US$ 22 billion by end 2027.
Under the MoU, GWRL will establish an aerostat envelope production facility and Aero-T will providing the technology and know-how for the aerostats development and production
Technical textile manufacturer Garware-Wall Ropes Ltd (GWRL) has signed an agreement with Israel's Aero-T to manufacture and supply advanced aerostats for Indian Defence.
Disclaimer: The contents herein is specifically prepared by ‘Dalal Street Investment Journal’, and is for your information & personal consumption only. India Infoline Limited or Dalal Street Investment Journal do not guarantee the accuracy, correctness, completeness or reliability of information contained herein and shall not be held responsible.
Larsen & Toubro Infotech, Agarwal Industrial Corporation , Dewan Housing Finance Corporation, Escorts, BEML, Yes Bank, Agro Tech Foods, Geometric, IndusInd Bank, Adani Power, Tata Steel, HPCL, BPCL, Biocon, Garware-Wall Ropes, Nahar Capital Financial Services, Insecticides India, Lumax Industries, GAIL, Tata Chemicals, Infibeam Incorporation, Minda Industries, Dhanuka Agritech and Kotak Mahindra Bank are the 25 stocks which are close to their 52-week high and should be kept an eye on, on February 27.
, GWRL has pledged to plant approximately 2 thousand trees in the vicinity of their Wai plant. The activity was inaugurated by Mrs. Vijayatai Ghosle - Host of Pratapghad Utsav Samiti.
2018-05-25 - Asif
Overview Heron is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments that address some of the most important unmet patient needs. Heron Therapeutics is developing novel, patient-focused solutions that apply its innovative science and technologies to already approved pharmacological agents for patients suffering from cancer or pain. On August 9, 2016, its first commercial product, SUSTOL, was approved by the FDA. The company developed SUSTOL for the prevention of chemotherapy-induced nausea and vomiting (“CINV”). SUSTOL is indicated, in combination with other antiemetics, in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (“MEC”) or anthracycline and cyclophosphamide (“AC”) combination chemotherapy regimens. The company commenced commercial sales of SUSTOL in the U.S. in October 2016. On November 9, 2017...
2018-05-25 - Asif
Overview The company's mission is to deliver high-speed coherent optical interconnect products that transform communications networks, relied upon by cloud infrastructure operators and content and communication service providers, through improvements in performance and capacity and reductions in associated costs. By converting optical interconnect technology to a silicon-based technology, a process the company refer to as the siliconization of optical interconnect, the company believe Acacia Communications is leading a disruption that is analogous to the computing industry’s integration of multiple functions into a microprocessor. The company's products include a family of low-power coherent digital signal processor application-specific integrated circuits, or DSP ASICs, and silicon photonic integrated circuits, or silicon PICs, which Acacia Communications has integrated into families of optical interconnect modules with transmission speeds ranging from 100 to 400 gigabits per ...
2018-05-21 - Asif
Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...